RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced that data from two clinical studies with PMX-60056 will be presented at the scientific sessions of the upcoming 2010 American Heart Association Meeting. PMX-60056 is a synthetic small molecule designed to reverse the anticoagulant activity of both heparin and low molecular weight heparins. The meeting will take place at the McCormick Place Convention Center in Chicago, Illinois from November 13-17, 2010.
